<?xml version='1.0' encoding='utf-8'?>
<document id="24861133"><sentence text="Pharmacokinetic interaction study of ticagrelor and cyclosporine in healthy volunteers."><entity charOffset="37-47" id="DDI-PubMed.24861133.s1.e0" text="ticagrelor" /><entity charOffset="52-64" id="DDI-PubMed.24861133.s1.e1" text="cyclosporine" /><pair ddi="false" e1="DDI-PubMed.24861133.s1.e0" e2="DDI-PubMed.24861133.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24861133.s1.e0" e2="DDI-PubMed.24861133.s1.e1" /></sentence><sentence text="Patients with acute coronary syndrome and certain co-morbidities may receive ticagrelor, a reversibly binding P2Y(12) receptor antagonist, and cyclosporine, a commonly used immunosuppressant drug"><entity charOffset="143-155" id="DDI-PubMed.24861133.s2.e0" text="cyclosporine" /></sentence><sentence text=" This study assessed the potential pharmacokinetic drug-drug interaction between ticagrelor and cyclosporine"><entity charOffset="96-108" id="DDI-PubMed.24861133.s3.e0" text="cyclosporine" /></sentence><sentence text="" /><sentence text="In this single-centre, open-label, three-treatment, three-period crossover study (NCT01504906), healthy volunteers (n = 26) randomly received each of three treatments: cyclosporine (600 mg single oral dose) plus ticagrelor (180 mg single oral dose); cyclosporine alone; ticagrelor alone"><entity charOffset="168-180" id="DDI-PubMed.24861133.s5.e0" text="cyclosporine" /><entity charOffset="212-222" id="DDI-PubMed.24861133.s5.e1" text="ticagrelor" /><entity charOffset="250-262" id="DDI-PubMed.24861133.s5.e2" text="cyclosporine" /><entity charOffset="270-280" id="DDI-PubMed.24861133.s5.e3" text="ticagrelor" /><pair ddi="false" e1="DDI-PubMed.24861133.s5.e0" e2="DDI-PubMed.24861133.s5.e0" /><pair ddi="false" e1="DDI-PubMed.24861133.s5.e0" e2="DDI-PubMed.24861133.s5.e1" /><pair ddi="false" e1="DDI-PubMed.24861133.s5.e0" e2="DDI-PubMed.24861133.s5.e2" /><pair ddi="false" e1="DDI-PubMed.24861133.s5.e0" e2="DDI-PubMed.24861133.s5.e3" /><pair ddi="false" e1="DDI-PubMed.24861133.s5.e1" e2="DDI-PubMed.24861133.s5.e1" /><pair ddi="false" e1="DDI-PubMed.24861133.s5.e1" e2="DDI-PubMed.24861133.s5.e2" /><pair ddi="false" e1="DDI-PubMed.24861133.s5.e1" e2="DDI-PubMed.24861133.s5.e3" /><pair ddi="false" e1="DDI-PubMed.24861133.s5.e2" e2="DDI-PubMed.24861133.s5.e2" /><pair ddi="false" e1="DDI-PubMed.24861133.s5.e2" e2="DDI-PubMed.24861133.s5.e3" /></sentence><sentence text=" Treatments were separated by a washout period of ≥14 days" /><sentence text=" Plasma concentrations of ticagrelor and its active metabolite (AR-C124910XX) and blood concentrations of cyclosporine were analyzed, and pharmacokinetic parameters were calculated"><entity charOffset="26-36" id="DDI-PubMed.24861133.s7.e0" text="ticagrelor" /><entity charOffset="106-118" id="DDI-PubMed.24861133.s7.e1" text="cyclosporine" /><pair ddi="false" e1="DDI-PubMed.24861133.s7.e0" e2="DDI-PubMed.24861133.s7.e0" /><pair ddi="false" e1="DDI-PubMed.24861133.s7.e0" e2="DDI-PubMed.24861133.s7.e1" /></sentence><sentence text=" Safety and tolerability were assessed" /><sentence text="" /><sentence text="Compared with ticagrelor alone, the geometric least squares mean (LSM) ratio (90 % confidence interval [CI]) for the ticagrelor area under the plasma concentration-time curve from time zero to infinity (AUC(∞)) was 2"><entity charOffset="14-24" id="DDI-PubMed.24861133.s10.e0" text="ticagrelor" /></sentence><sentence text="83 (2" /><sentence text="63-3" /><sentence text="06), and the maximum plasma concentration (C(max)) was 2" /><sentence text="30 (2" /><sentence text="06-2" /><sentence text="58), in the presence of cyclosporine"><entity charOffset="24-36" id="DDI-PubMed.24861133.s16.e0" text="cyclosporine" /></sentence><sentence text=" Co-administration of cyclosporine with ticagrelor significantly increased AR-C124910XX AUC(∞) (1"><entity charOffset="22-34" id="DDI-PubMed.24861133.s17.e0" text="cyclosporine" /><entity charOffset="40-50" id="DDI-PubMed.24861133.s17.e1" text="ticagrelor" /><pair ddi="false" e1="DDI-PubMed.24861133.s17.e0" e2="DDI-PubMed.24861133.s17.e0" /><pair ddi="false" e1="DDI-PubMed.24861133.s17.e0" e2="DDI-PubMed.24861133.s17.e1" /></sentence><sentence text="33 [1" /><sentence text="23-1" /><sentence text="42]) and decreased C(max) (0" /><sentence text="85 [0" /><sentence text="76-0" /><sentence text="94])" /><sentence text=" Ticagrelor had no effect on cyclosporine pharmacokinetic parameters, as the 90 % CIs of the LSM ratios were all within the 0"><entity charOffset="1-11" id="DDI-PubMed.24861133.s24.e0" text="Ticagrelor" /><entity charOffset="29-41" id="DDI-PubMed.24861133.s24.e1" text="cyclosporine" /><pair ddi="false" e1="DDI-PubMed.24861133.s24.e0" e2="DDI-PubMed.24861133.s24.e0" /><pair ddi="false" e1="DDI-PubMed.24861133.s24.e0" e2="DDI-PubMed.24861133.s24.e1" /></sentence><sentence text="80-1" /><sentence text="25 no-effect range" /><sentence text=" Co-administration of ticagrelor and cyclosporine was generally well tolerated"><entity charOffset="22-32" id="DDI-PubMed.24861133.s27.e0" text="ticagrelor" /><entity charOffset="37-49" id="DDI-PubMed.24861133.s27.e1" text="cyclosporine" /><pair ddi="false" e1="DDI-PubMed.24861133.s27.e0" e2="DDI-PubMed.24861133.s27.e0" /><pair ddi="false" e1="DDI-PubMed.24861133.s27.e0" e2="DDI-PubMed.24861133.s27.e1" /></sentence><sentence text="" /><sentence text="Co-administration of cyclosporine with ticagrelor increased exposure to ticagrelor and its active metabolite and had no effect on cyclosporine pharmacokinetic parameters"><entity charOffset="21-33" id="DDI-PubMed.24861133.s29.e0" text="cyclosporine" /><entity charOffset="130-142" id="DDI-PubMed.24861133.s29.e1" text="cyclosporine" /><pair ddi="false" e1="DDI-PubMed.24861133.s29.e0" e2="DDI-PubMed.24861133.s29.e0" /><pair ddi="false" e1="DDI-PubMed.24861133.s29.e0" e2="DDI-PubMed.24861133.s29.e1" /></sentence><sentence text=" The magnitude of cyclosporine's effect on ticagrelor pharmacokinetics does not warrant dose adjustment of ticagrelor" /><sentence text="" /></document>